Main menu

Implementing next generation sequencing for rapid diagnostics and public health investigations


Kimberlee Musser, PhD, is the Clinical Director and the Chief of Bacterial Disease for the Wadsworth Center, NYSDOH. She has overseen bacterial public health reference testing, surveillance, and outbreak investigations in NY for more than 25 years following a CDC/APHL Emerging Infectious Diseases postdoctoral fellowship. Her laboratory has developed and validated >100 laboratory-developed tests including real-time PCR assays, MALDI-TOF Mass Spectrometry, pyrosequencing, and most recently next generation sequencing for clinical and public health testing.

Abstract

The objective of this project is to develop and validate Oxford Nanopore sequencing tests for use on clinical specimens and isolates with improved performance, cost, and efficiency for applications ranging from Mycobacterium tuberculosis (MTB) whole genome and targeted sequencing, bacterial identification, and for healthcare associated transmission investigations of antimicrobial resistant and other bacterial pathogens.

Authors: Kim Musser, Clinical Director, Wadsworth Center, David Axelrod Institute

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag